Gefitinib

Gefitinib is a selective EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC). Mediocon Inc supplies pharmaceutical-grade Gefitinib API meeting IP/BP/EP/USP standards.

Key Features

• Selective EGFR tyrosine kinase inhibitor
• First-line NSCLC treatment agent
• IP/BP/EP/USP compliant
• Full CoA and MSDS documentation

Applications

• Non-small cell lung cancer (NSCLC)
• EGFR mutation-positive lung cancer
• Targeted cancer therapy
• Oncology formulations

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings